However, the float is extremely thin. If they halt their stupid ATM program (which brings in bupkis) and let the stock ride on its own, it will be an easy trip to the 3s..
The detailed opinion letter should be out any day now. It may confirm the validity of the blocking patents which confirm the platform i.p. If this is the case, then DEPO may see new avenues to gain licensing revenues from other drugs, as well as strengthen their cases against Purdue and Endo. I don't expect them to recoup legal fees from Actavis, even though they petitioned the court for them.
The letter was rambling, patronizing, ungrammatical and overly focused on the negative aspects of the Company's portfolio. Sometimes, it's better not to communicate with shareholders. Nevertheless, I'm a buyer of TINY. I'm convniced that management's inability to communicate with shareholders is one of main reasons thestock is depressed.
Torrid volume continues. Shorts waiting for an exit, but the stock is at a dangerous inflection point (for them). Most out-of-the-money options have huge spreads making it difficult to hedge. She's incredibly resilient when one would expect a sell-on-the-news retracement. Analyst coverage should be coming as soon as Judge Pisano's opinion is published (any day now, in short order).
Some institutions insist that a stock trade above 15 for 10 consecutive days before bringing up a speculative buy to their investment committee. I think we have a chance before the end of the year, especially if we see some short covering.
Slight retracement. Alot of stock was flushed out recently when it dropped below 10 so expect a little back and fill. Fundamwentals are more important. A big legal cloud has disappeared and the sales force will be motivated to increase scripts. Expect one or two acquisitions prior to year end. If it's only 1, it will probably bigger than what we saw last year. They need to keep the sales force busy so they can earn a decent bonus.
It's not going to happen for a long time. I'm long DEPO, but these cases will take a long time. The hearings aren't scheduled until next year and the patents are also expiring. It will be a messy case trying to get retroactive damages. They may succeed in part from legal exhaustion on both sides, but the monies owed will not be earth shaking, IMHO.
That's why Genzyme was taken out for billions. Sometimes the cost of treatment for a single patient is over $300,000 plus the protection of Orphan Drug Status.
Perhaps they can use their stock as currency, or float a convert and preserve their cash. A more substantial acquisition appears to be on the way. They're waiting for the counterparty to come to terms.
He took a huge position when everyone thought they were down and out and now his fund will make a killing selling calls at higher strikes all day. He's the master os biotech and honors the memory of a great scientist, his father, Izzy.
ehead of tomorrow's conference call. For executives who are supposed to be Wall St savvy, it beats me why they come out with earings on a Friday after the close and a CC a week later.
Not that I expect a substantial move soon.. However, sometimes, a confirmatory bottom leads to a bounce. One can make alot of money if they frequently trade bounces. This Company doesn't have the resources to go it alone, so they may be buying some time while they put themselves up for sale. There are a limited number of potential buyers, who want her to bleed in the meantime, but sometimes an unexpected buyer comes out of nowhere. I'm betting on that scenario.
I think they'll buy something outside the pain space. It may still be in neurology, but the market is already flooded with pain drugs. Besides, they don't want to have a conflict with Mallinkrodt. Since Lazanda is sold to oncologists, they may consider something that their salesmen (a separate force) can peddle to this specialty group.